Orbite Provides Update on Refractory Material and High Purity Alumina Plant Construction

Orbite Aluminae Inc. ("Orbite" or the "Company") today provided an update on the construction of its high purity alumina plant.

Refractory Material and Project Update

Orbite had announced on October 29th that, following quality control testing by the Company's Technology Development Centre (TDC), product non conformities had been identified with some of the refractory materials supplied by Outotec which could have led to mechanical integrity problems during operations. Specifically, the non-conformities were found in the mortar and the castables supplied.

Orbite then identified and tested replacement materials that could be used to replace the brick and mortar inner lining of the decomposer and calcinator (castable monolith), with no detrimental impact on product quality.

Orbite reported on December 4th, following extensive testing of refractory materials at the Company's TDC that the brick and mortar refractory approach had been selected, instead of a castable monolith for the inner lining of its decomposer and calcinator.

The initially supplied non-conforming mortar will be replaced with a new mortar formulation, sourced from Outotec, anticipated to arrive in Canada in December, as planned. The non-conforming castable material will not be replaced by an Outotec product, but by the alternative proprietary material, sourced from a third party supplier, and tested and approved by Orbite's TDC.

Some of the components of this new castable are sourced from a European manufacturer. Orbite has been informed by its supplier that, contrary to earlier communicated timelines, the components from Europe will not be available until the end of February 2015, leading to commencement of refractory system installation at the end of March 2015.

Consequently, the commencement of commercial production at the HPA facility has been deferred by one quarter to Q3 2015.

Orbite has received and is presently evaluating refractory installation bids from 3 specialized contractors, and expects to award the contract shortly.

HPA Project Budget

Orbite had originally estimated project costs at $31.0M (see June 2013 release), based upon cost estimates prepared by 2 external engineering firms, to complete the plant construction work undertaken in 2012, based on the then contemplated plant design. This estimate was subsequently scaled back to $28.5M after excluding some of the construction work related to the front end (extraction section) of the HPA plant.

The engineering review, conducted throughout 2014, has shown that the original design of the 2012 HPA plant was inadequate to deliver at 3tpd capacity. Consequently, the facility was materially redesigned, and certain installed equipment and piping will be replaced to meet capacity and longevity specifications.

Accordingly, Orbite is increasing its project budget to approximately $42M (inclusive of a $3M contingency provision), representing an increase in total plant cost from $105.9M to $117M.

The incremental costs are due to the following:

  • Management decided to maximize the heating capacity in the Outotec calcination system in order to increase the ultimate calcinator capacity to 5tpd, resulting in higher than originally budgeted system costs. This increase in capacity could not have been fitted at a later date, and committing to this change now significantly reduces costs associated with subsequent capacity increases.
  • Engineering costs will be higher than forecasted, related to the additional work needed.
  • The project delay resulting from the non-conforming refractory supply will lead to increased project management costs.
  • Some of the work originally excluded from the front end of the plant has been reinstated in the project.
  • Certain equipment and piping, planned to be reused, will be replaced.
  • The refractory solution selected will require additional installation work, in part related to the replacement of some preinstalled castables in certain piping sections of the decomposer and calcinator.
  • Recently received costs for some specialty piping and equipment are higher than forecasted.

Project Financing

The additional funds required to complete the HPA production facility are available to the Company under the Series Y Subscription Rights agreement with Crede. The Company has until January 30 to call a special meeting of shareholders to approve the Crede funding. In the interim, the Company continues to explore alternative funding sources.

"Our primary concern is the commissioning of a properly designed HPA facility that will deliver consistent output of high quality products, while at the same time facilitating a more economical upgrade to a 5tpd capacity," stated Glenn Kelly, CEO of Orbite.

About Orbite

Orbite Aluminae Inc. is a Canadian cleantech company whose innovative and proprietary processes are expected to produce alumina and other high-value products, such as rare earth and rare metal oxides, at one of the lowest costs in the industry, and in a sustainable fashion, using feedstocks that include aluminous clay, kaolin, nepheline, bauxite, red mud, fly ash as well as serpentine residues from chrysotile processing sites. Orbite is currently in the process of finalizing its first commercial high-purity alumina (HPA) production plant in Cap-Chat, Québec and has completed the basic engineering for a proposed smelter-grade alumina (SGA) production plant, which would use clay mined from its Grande-Vallée deposit. The Company's portfolio contains 15 intellectual property families, including 12 patents and 95 pending patent applications in 10 different countries and regions. The first intellectual property family is patented in Canada, USA, Australia, China, Japan and Russia. The Company also operates a state of the art technology development center in Laval, Québec, where its technologies are developed and validated.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.